Foamix Pharmaceuticals Ltd.
DelistedCIK 1606645fmd_1EW2NK932HYSPR9K95TDDKYMSFManufacturing · Medicinal Chemicals & Botanical ProductsTemplate: Standard
Coverage: Jan 01, 2012 to Dec 31, 2019, 22 periods
Latest annual · FY2019
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (96)
- Net income
- (95)
- Free cash flow
- (74)
Latest quarter · Q4 FY2019
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (37)
- Net income
- (38)
- Free cash flow
- (22)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2016 to FY2019
- -56.9%
- Revenue, 5 yearsFY2014 to FY2019
- -39.4%
- Net income, 5 yearsFY2014 to FY2019
- n/m
Foamix Pharmaceuticals Ltd. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2019 | FY2018 | Change | Source |
|---|---|---|---|---|
| Revenue | $443,000 | $3.6 million | -87.7% | 10-K 2020-03-12 · proof |
| Gross profit | $443,000 | $3.6 million | -87.7% | 10-K 2020-03-12 · proof |
| Operating income | -$95.9 million | -$74.9 million | 10-K 2020-03-12 · proof | |
| Net income | -$95.2 million | -$74.2 million | 10-K 2020-03-12 · proof | |
| Cash from operating activities | -$73.4 million | -$68.7 million | 10-K 2020-03-12 · proof | |
| Free cash flow | -$74.5 million | -$69.2 million | 10-K 2020-03-12 · proof | |
| Total assets | $81.2 million | $103.7 million | -21.8% | 10-K 2020-03-12 · proof |
| Total liabilities | $63.6 million | $11.5 million | +450.6% | 10-K 2020-03-12 · proof |
| Cash and cash equivalents | $43.8 million | $27.9 million | +57% | 10-K 2020-03-12 · proof |
- What was Foamix Pharmaceuticals Ltd.'s revenue in fiscal 2019?
- Foamix Pharmaceuticals Ltd. reported revenue of $443,000 for fiscal 2019 (the year ended Dec 31, 2019), against $3.6 million the year before (-87.7%). Source: the 10-K filed with the SEC on Mar 12, 2020. SEC
- What was Foamix Pharmaceuticals Ltd.'s gross profit in fiscal 2019?
- Foamix Pharmaceuticals Ltd. reported gross profit of $443,000 for fiscal 2019 (the year ended Dec 31, 2019), against $3.6 million the year before (-87.7%). Source: the 10-K filed with the SEC on Mar 12, 2020. SEC
- What was Foamix Pharmaceuticals Ltd.'s operating income in fiscal 2019?
- Foamix Pharmaceuticals Ltd. reported operating income of -$95.9 million for fiscal 2019 (the year ended Dec 31, 2019), against -$74.9 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2020. SEC
- What was Foamix Pharmaceuticals Ltd.'s net income in fiscal 2019?
- Foamix Pharmaceuticals Ltd. reported net income of -$95.2 million for fiscal 2019 (the year ended Dec 31, 2019), against -$74.2 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2020. SEC
- What was Foamix Pharmaceuticals Ltd.'s cash from operating activities in fiscal 2019?
- Foamix Pharmaceuticals Ltd. reported cash from operating activities of -$73.4 million for fiscal 2019 (the year ended Dec 31, 2019), against -$68.7 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2020. SEC
- What was Foamix Pharmaceuticals Ltd.'s free cash flow in fiscal 2019?
- Foamix Pharmaceuticals Ltd. reported free cash flow of -$74.5 million for fiscal 2019 (the year ended Dec 31, 2019), against -$69.2 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2020. SEC
- What are Foamix Pharmaceuticals Ltd.'s total assets?
- As of Dec 31, 2019, Foamix Pharmaceuticals Ltd. reported total assets of $81.2 million, against $103.7 million a year earlier (-21.8%). Source: the 10-K filed with the SEC on Mar 12, 2020. SEC
- What are Foamix Pharmaceuticals Ltd.'s total liabilities?
- As of Dec 31, 2019, Foamix Pharmaceuticals Ltd. reported total liabilities of $63.6 million, against $11.5 million a year earlier (+450.6%). Source: the 10-K filed with the SEC on Mar 12, 2020. SEC
- What are Foamix Pharmaceuticals Ltd.'s cash and cash equivalents?
- As of Dec 31, 2019, Foamix Pharmaceuticals Ltd. reported cash and cash equivalents of $43.8 million, against $27.9 million a year earlier (+57%). Source: the 10-K filed with the SEC on Mar 12, 2020. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1606645&period_type=annual&limit=5"Information only, not investment advice.